Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v8-EN Version v5-FR
Language English French
Date Updated 2021-09-16 2021-08-27
Drug Identification Number 02491680 02491680
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 1 mL HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients HYDROMORPHONE HYDROCHLORIDE HYDROMORPHONE HYDROCHLORIDE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1 mL 1 mL
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2021-07-30 2021-07-30
Actual start date 2021-07-30 2021-07-30
Estimated end date 2021-09-13 2021-09-13
Actual end date 2021-09-15
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Situation is resolved. resenius Kabi Canada Ltd. regrets to advise that due to production and shipping delays, our HYDROmorphone Hydrochloride Injection, USP 10 mg/mL SD Vial 1 mL will be going on backorder. Sandoz is an alternate supplier of HYDROmorphone Hydrochloride Injection, USP and has been informed of our impending supply interruption.
Health Canada comments